Celltrion Healthcare

Celltrion Healthcare conducts the worldwide marketing, sales and distribution of biological medicines developed by Celltrion, Inc. through an extensive global network that spans more than 120 different countries. Celltrion Healthcare’s products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US Food and Drug Administration (FDA) cGMP guidelines and the EU GMP guidelines.

 Inflectra® / Remsima® (CT-P13, biosimilar infliximab) which is the world’s first monoclonal antibody (mAb) biosimilar, received FDA and EMA approval, respectively. Truxima® (CT-P10, biosimilar rituximab) also received EMA approval in February 2017, and Herzuma® (CT-P6, biosimilar trastuzumab) in February 2018.